Proliferation News and Research

RSS

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Fracture bracing systems: an interview with Steve Ingel, President for the Bracing & Supports Division of DJO Global

Surprisingly, there are significantly more medical treatment episodes for upper extremity fractures than for those of lower extremity. The vast majority of forearm, hand and wrist fractures occur in pediatrics and young adults as they tend to be more active and involved in sporting activities.

6 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.

3 Nov 2012

CD22 protein could prove to be important new target for anti-cancer therapy

A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy. A series of experiments in mice with lung cancer showed that specific targeting of the protein with monoclonal antibodies reduced the size of tumors, lowered the occurrence of metastases and substantially lengthened survival time.

2 Nov 2012

Nisin may slow or prevent squamous cell head and neck cancers

Nisin, a common food preservative, may slow or stop squamous cell head and neck cancers, a University of Michigan study found.

1 Nov 2012

Cilostazol reduces restenosis after angioplasty in critical limb ischemia

The quinolinone derivative cilostazol may be associated with reduced restenosis, reocclusion, and clinically driven target lesion revascularization 3 months after infrapopliteal angioplasty, researchers say.

30 Oct 2012

Study identifies new prognostic biomarker and therapeutic target for adult B-ALL

New insight into the aggressive behavior of certain adult B-acute lymphoblastic leukemias has provided researchers with a potential new prognostic biomarker and a promising new therapeutic target.

30 Oct 2012

Botanical treatment holds hope for triple-negative breast cancer

A unique formula made from medicinal mushrooms, traditional Chinese herbs and other natural ingredients inhibits aggressive, human triple-negative breast cancer and breast-to-lung metastasis in mice. This is the third peer-reviewed study to demonstrate the botanical formula's anticancer effects.

29 Oct 2012

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Sea water therapy is a technique of cellular nutrition backed by more than 100 years of clinical use in hospitals, during which numerous studies have demonstrated its beneficial effects on patients' health.

29 Oct 2012

RUB-medical researchers receive $2.3M Gates Foundation grant for HIV vaccine research

To support their research for a vaccine against the HI-Virus, Prof. Dr. Klaus Überla of the Faculty for Medicine at the Ruhr-Universität Bochum and his research team will receive $2.3 million in funding within the next three years from the Bill & Melinda Gates Foundation. The scientists are part of the Collaboration for AIDS Vaccine Discovery (CAVD), which seeks to speed up the development of an HIV-vaccine through a rigorous exchange of information, methods and reagents.

29 Oct 2012

Cellectis announces successful programming of immune system cells to kill cancer cells

Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.

29 Oct 2012

Researchers zero in on process by which stem cells maintain proper undifferentiated state

The ability of embryonic stem cells to differentiate into different types of cells with different functions is regulated and maintained by a complex series of chemical interactions, which are not well understood. Learning more about this process could prove useful for stem cell-based therapies down the road. New research from a team led by Carnegie's Yixian Zheng zeroes in on the process by which stem cells maintain their proper undifferentiated state.

29 Oct 2012

Glioblastoma multiforme can originate from cortical neurons

Scientists have long believed that glioblastoma multiforme (GBM), the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. In a paper published October 18 in Science Express, however, researchers at the Salk Institute for Biological Studies have found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons.

23 Oct 2012

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.

22 Oct 2012

VEGF produced by NPCs plays a strong role in influencing microglial behavior

The brain's key "breeder" cells, it turns out, do more than that. They secrete substances that boost the numbers and strength of critical brain-based immune cells believed to play a vital role in brain health. This finding adds a new dimension to our understanding of how resident stem cells and stem cell transplants may improve brain function.

22 Oct 2012

ACT TIL therapy effective in treating metastatic melanoma

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL).

19 Oct 2012

New book focuses on Wnt signaling

Wnt proteins are signaling molecules that play critical roles during embryonic development and in the regeneration of adult tissues. They bind to Frizzled and LRP family receptors on the cell surface, triggering a series of events that cause beta-catenin to enter the nucleus and activate transcription factors that control cell fate and cell proliferation. Mutations in components of the Wnt pathway lead to developmental defects and are common in cancer.

19 Oct 2012

Research may lead to new ways to identify women with breast cancer risks from low-dose radiation

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory have identified tissue mechanisms that may influence a woman's susceptibility or resistance to breast cancer after exposure to low-dose ionizing radiation, such as the levels used in full-body CT scans and radiotherapy.

18 Oct 2012

Study determines how Trop2 protein drives growth of tumor cells in prostate and other epithelial cancers

Researchers led by Tanya Stoyanova and Dr. Owen Witte of UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have determined how a protein known as Trop2 drives the growth of tumor cells in prostate and other epithelial cancers.

17 Oct 2012

Proliferation News and Research

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Fracture bracing systems: an interview with Steve Ingel, President for the Bracing & Supports Division of DJO Global

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

CD22 protein could prove to be important new target for anti-cancer therapy

Nisin may slow or prevent squamous cell head and neck cancers

Cilostazol reduces restenosis after angioplasty in critical limb ischemia

Study identifies new prognostic biomarker and therapeutic target for adult B-ALL

Botanical treatment holds hope for triple-negative breast cancer

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

RUB-medical researchers receive $2.3M Gates Foundation grant for HIV vaccine research

Cellectis announces successful programming of immune system cells to kill cancer cells

Researchers zero in on process by which stem cells maintain proper undifferentiated state

Glioblastoma multiforme can originate from cortical neurons

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

VEGF produced by NPCs plays a strong role in influencing microglial behavior

ACT TIL therapy effective in treating metastatic melanoma

New book focuses on Wnt signaling

Research may lead to new ways to identify women with breast cancer risks from low-dose radiation

Study determines how Trop2 protein drives growth of tumor cells in prostate and other epithelial cancers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News